BRCA1, BRCA2 and PALB2 mRNA Expression as Prognostic Markers in Patients with Early Breast Cancer

被引:1
|
作者
Shehaj, Ina [1 ]
Krajnak, Slavomir [1 ]
Almstedt, Katrin [1 ]
Degirmenci, Yaman [1 ]
Herzog, Sophia [1 ]
Lebrecht, Antje [1 ]
Linz, Valerie Catherine [1 ]
Schwab, Roxana [1 ]
Stewen, Kathrin [1 ]
Brenner, Walburgis [1 ]
Hasenburg, Annette [1 ]
Schmidt, Marcus [1 ]
Heimes, Anne-Sophie [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Obstet & Gynecol, D-55131 Mainz, Germany
关键词
mRNA expression; BRCA1; BRCA2; PALB2; metagene; breast cancer; HETEROGENEITY; PROTEIN; IMPACT;
D O I
10.3390/biomedicines12061361
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast cancer (BC) poses a challenge in establishing new treatment strategies and identifying new prognostic and predictive markers due to the extensive genetic heterogeneity of BC. Very few studies have investigated the impact of mRNA expression of these genes on the survival of BC patients. Methods: We examined the impact of the mRNA expression of breast cancer gene type 1 (BRCA1), breast cancer gene type 2 (BRCA2), and partner and localizer of BRCA2 (PALB2) on the metastasis-free survival (MFS) of patients with early BC using microarray gene expression analysis. Results: The study was performed in a cohort of 461 patients with a median age of 62 years at initial diagnosis. The median follow-up time was 147 months. We could show that the lower expression of BRCA1 and BRCA2 is significantly associated with longer MFS (p < 0.050). On the contrary, the lower expression of PALB2 was correlated with a shorter MFS (p = 0.049). Subgroup survival analysis identified the prognostic influence of mRNA expression for BRCA1 among patients with luminal-B-like BC and for BRCA2 and PALB2 in the subset of patients with luminal-A-like BC (p < 0.050). Conclusions: According to our observations, BRCA1, BRCA2, and PALB2 expression might become valuable biomarkers of disease progression.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2
    Zhang, Fan
    Fan, Qiang
    Ren, Keqin
    Andreassen, Paul R.
    MOLECULAR CANCER RESEARCH, 2009, 7 (07) : 1110 - 1118
  • [2] A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago
    Donenberg, Talia
    Ahmed, Humayun
    Royer, Robert
    Zhang, Shiyu
    Narod, Steven A.
    George, Sophia
    Akbari, Mohammad R.
    Ali, Jameel
    Hurley, Judith
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (01) : 131 - 138
  • [3] A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago
    Talia Donenberg
    Humayun Ahmed
    Robert Royer
    Shiyu Zhang
    Steven A. Narod
    Sophia George
    Mohammad R. Akbari
    Jameel Ali
    Judith Hurley
    Breast Cancer Research and Treatment, 2016, 159 : 131 - 138
  • [4] Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
    Wojcik, P.
    Jasiowka, M.
    Strycharz, E.
    Sobol, M.
    Hodorowicz-Zaniewska, D.
    Skotnicki, P.
    Byrski, T.
    Blecharz, P.
    Marczyk, E.
    Cedrych, I.
    Jakubowicz, J.
    Lubinski, J.
    Sopik, V.
    Narod, S.
    Pierzchalski, P.
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2016, 14
  • [5] Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
    P. Wojcik
    M. Jasiowka
    E. Strycharz
    M. Sobol
    D. Hodorowicz-Zaniewska
    P. Skotnicki
    T. Byrski
    P. Blecharz
    E. Marczyk
    I. Cedrych
    J. Jakubowicz
    J. Lubiński
    V. Sopik
    S. Narod
    P. Pierzchalski
    Hereditary Cancer in Clinical Practice, 14
  • [6] Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families
    Pylkas, Katri
    Erkko, Hannele
    Nikkila, Jenni
    Solyom, Szilvia
    Winqvist, Robert
    BMC CANCER, 2008, 8 (1)
  • [7] Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families
    Katri Pylkäs
    Hannele Erkko
    Jenni Nikkilä
    Szilvia Sólyom
    Robert Winqvist
    BMC Cancer, 8
  • [8] NGS-based BRCA1, BRCA2, and PALB2 mutation testing in Iranian population with breast cancer
    Ebrahimi, E.
    Zendehdel, K.
    Sellars, E.
    Ghiasvand, R.
    Harirchi, I.
    Shirkoohi, R.
    Akbari, M. R.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 531 - 532
  • [9] PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response
    Zhang, Feng
    Ma, Jianglin
    Wu, Jiaxue
    Ye, Lin
    Cai, Hong
    Xia, Bing
    Yu, Xiaochun
    CURRENT BIOLOGY, 2009, 19 (06) : 524 - 529
  • [10] The frequency of HER2-low breast cancer among BRCA1, BRCA2, and PALB2 mutation carriers
    Goldblatt, Lindsay
    Coutifaris, Paulina
    Shah, Payal Deepak
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)